Journal
THROMBOSIS RESEARCH
Volume 125, Issue -, Pages S30-S35Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/S0049-3848(10)70009-8
Keywords
Anticoagulants; Thrombin inhibitors; Factor Xa inhibitors; Venous thromboembolism; Cancer
Categories
Funding
- Canadian Institutes of Health Research [MOP3992, CTP79846] Funding Source: Medline
Ask authors/readers for more resources
Cancer-associated thrombosis is a major cause of morbidity and mortality. Although anticoagulation remains the mainstay for prevention and treatment of thrombosis, current anticoagulants are problematic in cancer patients. Parenteral anticoagulants, such as heparin or low-molecular heparin, require daily subcutaneous injection, whereas warfarin requires coagulation monitoring and frequent dose adjustments. Idrabiotaparinux, a reversible long-acting pentasaccharide, and new oral anticoagulants, such as dabigatran etexilate, rivaroxaban and apixaban, have been designed to replace warfarin for extended prevention or treatment of VTE. Clinical trials with these agents have yielded promising results, and dabigatran etexilate and rivaroxaban are already licensed in many countries for thromboprophylaxis after elective hip or knee replacement surgery. In the coming years, these drugs are likely to replace warfarin for most indications. This paper addresses their potential role for prevention and treatment of cancer-related thrombosis. (C) 2010 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available